Vibrating Capsule Reveals Gut-Brain Biomarkers for Anorexia Relapse

By Bio-IT World News Staff 

August 4, 2026 | An ingestible vibrating capsule combined with computational modeling of gut-brain signaling may help identify patients with anorexia nervosa (AN) at risk of relapse while opening the door to new therapeutic strategies, according to research published in JAMA Psychiatry (DOI: 10.1001/jamapsychiatry.2026.1301). 

The study, led by Sahib Khalsa, M.D., Ph.D., psychiatrist, neuroscientist, and associate professor in residence and director of anxiety disorders research at the UCLA Semel Institute for Neuroscience and Human Behavior, builds on growing evidence that gastrointestinal signaling — the brain's ability to sense and interpret signals from the digestive tract — plays a central role in AN and the high rates of relapse. Up to half of patients relapse within one to two years after discharge from inpatient treatment, underscoring the need for objective biomarkers that can guide long-term care. 

Researchers evaluated 62 females, ages 13 to 40, who had recently restored healthy body weight following hospitalization for AN, along with 57 healthy controls. Participants swallowed an FDA-cleared vibrating capsule originally developed to treat chronic idiopathic constipation. The device delivered remotely controlled stomach vibrations while investigators simultaneously recorded brain activity, heart rate, gastric rhythms, and self-reported hunger. Patients with AN were followed for six months after discharge. 

The team analyzed the data using a computational model that estimated participants’ expectations for internal stomach sensations, how much their brain depended on incoming sensory information, and how quickly those expectations were updated when the signals were detected. Compared with healthy controls, participants with AN were less accurate at detecting subtle stomach sensations, more likely to assume no sensation was present even when the pill was vibrating, and slower to revise those expectations. Several of these gut-brain measures were associated with relapse risk and symptom severity during follow-up. 

According to Khalsa, the findings demonstrate that non-pharmacologic technologies can generate both diagnostic and prognostic information in eating disorders. The approach could also be explored in other disorders of gut-brain interaction, including irritable bowel syndrome and functional dyspepsia. 

The study also revealed an unexpected finding: the vibrating capsule increased reports of hunger sensations in patients with AN than in healthy controls. Khalsa said future studies will need to examine whether mechanosensory stimulation could be incorporated into treatment, helping patients become more sensitive to natural hunger cues through guided interoceptive training. 

To read the full story by Deborah Borfitz, visit Diagnostics World News.